SEC Form 4 · accession 0001140361-15-042246
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Farrell
Officer — Chief Executive Officer
Period of report
Nov 16, 2015
Accepted (ET)
Nov 18, 2015 · 9:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Nov 16, 2015 | M | 5,975 | $33.70 | A | 150,853 | D | |
| ResMed Common StockF3 | Nov 16, 2015 | S | 5,975 | $57.03 | D | 144,878 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF2 | $33.70 | Nov 16, 2015 | M | 5,975 | D | Nov 11, 2010 | Nov 11, 2017 | ResMed Commmon Stock | 5,975 | 69,025 | D |
Explanation of responses
- F1The transaction was conducted under a 10b5-1 Plan as defined under the Securities Exchange Act of 1934, as amended.
- F2Represents date options first became exercisable. Options vest 1/4 annually.
- F3This transaction was executed in multiple trades at prices ranging from $56.93 to $57.10. The price reported above reflects the weighted average sale price. The reporting person will provide full information regarding the number of shares and prices at which the transaction was effected upon request to the SEC staff, the issuer or the security holder of the issuer.